PGEN - Precigen Inc Stock Price, Fair Value and News

1.38USD-0.02 (-1.43%)Market Closed

Market Summary

USD1.38-0.02

Market Closed

-1.43%

PGEN Stock Price

View Fullscreen

PGEN RSI Chart

PGEN Valuation

Market Cap

348.3M

Price/Earnings (Trailing)

-3.59

Price/Sales (Trailing)

15.53

EV/EBITDA

-3.65

Price/Free Cashflow

-5.1

PGEN Price/Sales (Trailing)

PGEN Profitability

EBT Margin

-440.39%

Return on Equity

-99.89%

Return on Assets

-71.87%

Free Cashflow Yield

-19.63%

PGEN Fundamentals

PGEN Revenue

Revenue (TTM)

22.1M

PGEN Earnings

Earnings (TTM)

-96.9M

Earnings Growth (Yr)

-4.42%

Earnings Growth (Qtr)

28.19%

Breaking Down PGEN Revenue

Last 7 days

8.7%

Last 30 days

5.3%

Last 90 days

-2.8%

Trailing 12 Months

10.4%

How does PGEN drawdown profile look like?

PGEN Financial Health

Current Ratio

1.72

PGEN Investor Care

Buy Backs (1Y)

1.20%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	23.2M	22.1M	0	0
2022	16.3M	15.4M	28.8M	26.9M
2021	97.9M	71.2M	51.0M	35.3M
2020	98.0M	95.6M	100.8M	103.2M
2019	134.1M	121.7M	107.5M	90.7M
2018	217.1M	208.0M	194.4M	151.2M
2017	201.2M	203.2M	200.2M	231.2M
2016	183.2M	190.8M	186.4M	190.9M
2015	97.9M	131.0M	163.2M	173.6M
2014	27.7M	32.8M	48.0M	71.9M
2013	16.1M	20.1M	23.2M	23.8M
2012	9.5M	10.9M	12.3M	13.8M
2011	0	0	0	8.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Precigen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	kirk randal j	sold	-	-	-8,790,670	-
May 02, 2024	perez jeffrey thomas	acquired	-	-	126,713	svp, ip affairs
May 02, 2024	kirk randal j	sold	-	-	-4,995,000	-
May 02, 2024	kirk randal j	sold	-	-	-1,383,860	-
May 02, 2024	kirk randal j	sold	-	-	-58,800	-
May 02, 2024	kirk randal j	sold	-	-	-59,133	-
May 02, 2024	kirk randal j	sold	-	-	-2,497,500	-
May 02, 2024	kirk randal j	sold	-	-	-832,500	-
May 02, 2024	kirk randal j	sold	-	-	-118,266	-
May 02, 2024	kirk randal j	acquired	-	-	8,896,410	-

Which funds bought or sold PGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-40.48	-10,608	19,192	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-55.41	-142,987	133,317	-%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-4.71	2,391	79,103	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-40.31	-252,216	460,021	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	new	-	46,262	46,262	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	76.82	1,235,430	2,588,080	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	sold off	-100	-21,967	-	-%
May 15, 2024	Graham Capital Management, L.P.	sold off	-100	-21,116	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-51.84	-1,826,370	1,987,150	-%
May 15, 2024	MSD Partners, L.P.	unchanged	-	39,050	514,750	0.04%

Are Funds Buying or Selling PGEN?

Are funds buying PGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PGEN

No. of Funds

Unveiling Precigen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 03, 2024	kirk randal j	36.9%	93,314,946	SC 13D/A
Feb 27, 2024	patient capital management, llc	6.42%	15,983,700	SC 13G/A
Feb 14, 2024	patient capital management, llc	6.42%	15,983,700	SC 13G
Feb 14, 2024	ares trading s.a.	8.3%	20,647,152	SC 13G/A
Jan 31, 2023	kirk randal j	38.3%	96,360,443	SC 13D/A
Jan 27, 2023	ares trading s.a.	9.92%	20,647,152	SC 13G/A
Oct 07, 2022	kirk randal j	40.7%	84,805,277	SC 13D/A
Jan 24, 2022	ares trading s.a.	9.99%	20,647,152	SC 13G/A
Feb 16, 2021	miller value partners, llc	3.85%	7,134,094	SC 13G/A
Jan 08, 2021	ares trading s.a.	14.8%	27,398,519	SC 13G/A

Recent SEC filings of Precigen Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	SC 13D/A	13D - Major Acquisition
Apr 29, 2024	10-K/A	Annual Report
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading

Peers (Alternatives to Precigen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Precigen Inc News

Latest updates

Precigen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-4.5%	1,767,000	1,851,000	1,763,000	16,722,000	2,911,000	5,513,000	3,684,000	3,333,000	3,815,000	24,511,000	19,333,000	23,583,000	30,424,000	29,838,000	17,002,000	18,299,000	32,836,000	22,585,000	33,789,000	32,448,000	45,275,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92,000	-37,480,500	2,480,000	2,200,000	82,038,000	-273,472,500	98,919,000	95,010,000
S&GA Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,741,000	21,483,000	33,594,000	24,935,000	38,708,000	34,427,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31,480,000	34,518,000	33,062,000	280,449,500	44,885,000	42,049,000
EBITDA Margin	0.8%	-2.78	-2.80	-2.31	-2.45	-5.59	-5.40	-2.43	-1.91	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-85.3%	136,000	924,000	624,500	2,036,000	2,063,000	3,535,000	-2,871,500	4,765,000	4,633,000	3,539,000	-2,778,500	4,646,000	4,592,000	3,568,000	-2,546,000	4,466,000	4,353,000	77,000	-372,000	3,999,000	142,000
Income Taxes	-18.2%	-65,000	-55,000	8,000	-50,000	-89,000	-58,000	-164,000	-	-	4,000	-130,000	8,000	-	40,000	-451,500	-512,000	-525,000	30,000	4,110,000	-14,322,000	-1,127,000
Earnings Before Taxes	10.6%	-20,384,000	-22,789,000	-22,168,000	-7,694,000	-26,148,000	-23,956,000	-29,188,500	-26,380,000	-30,999,000	-21,896,000	-40,303,000	-27,586,000	-15,829,000	-20,806,000	-36,980,000	-49,057,000	-32,314,000	-52,913,000	-203,393,000	-73,068,000	-67,956,000
EBT Margin	2.5%	-3.30	-3.39	-2.97	-3.02	-6.84	-6.76	-3.07	-2.35	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.6%	-20,319,000	-22,734,000	-22,176,000	87,379,000	-17,635,000	-19,251,000	-25,034,000	-29,764,000	-20,050,000	-17,318,000	-41,661,000	-29,508,000	-43,354,000	-55,998,000	-169,215,000	-53,634,000	-38,766,000	-60,709,000	-340,465,000	-57,324,000	-65,382,000
Net Income Margin	-6.2%	1.00	1.07	1.05	0.88	-5.94	-5.76	-2.61	-2.13	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	14.4%	-15,869,000	-18,542,000	-15,449,000	-25,387,000	-8,771,000	-20,362,000	-17,362,000	-19,288,000	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.7%	135	151	191	208	242	216	259	321	336	360	377	403	407	315	336	362	405	456	605	655	710
Current Assets	-27.9%	50.00	69.00	93.00	106	138	118	163	165	155	157	153	157	144	149	151	173	189	235	157	183	232
Cash Equivalents	134.1%	18.00	8.00	10.00	17.00	10.00	5.00	92.00	50.00	41.00	43.00	42.00	37.00	28.00	52.00	28.00	47.00	38.00	68.00	45.00	59.00	107
Net PPE	77.5%	13.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	34.00	9.00	33.00	33.00	34.00	35.00	45.00	47.00	60.00	44.00	123	120	136
Goodwill	-0.2%	27.00	27.00	37.00	37.00	37.00	37.00	37.00	37.00	54.00	38.00	54.00	54.00	54.00	38.00	54.00	54.00	64.00	54.00	148	150	151
Liabilities	16.2%	38.00	33.00	43.00	41.00	57.00	90.00	117	266	262	253	246	243	232	247	278	312	317	384	376	376	375
Current Liabilities	25.2%	29.00	23.00	33.00	31.00	47.00	79.00	105	30.00	26.00	35.00	29.00	29.00	25.00	42.00	31.00	64.00	71.00	123	82.00	52.00	59.00
Short Term Borrowings	-	-	-	-	-	14.00	43.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	199	201	180	180	177	174	172	194	191	189	186	184	212	214
LT Debt, Current	-	-	-	-	-	-	43.00	82.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.00	32.00	32.00	31.00	0.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	199	201	180	180	177	174	172	194	191	189	186	184	212	214
Shareholder's Equity	-18.1%	97.00	118	148	166	184	126	143	56.00	74.00	107	131	159	175	67.00	59.00	50.00	87.00	72.00	228	279	335
Retained Earnings	-1.2%	-1,988	-1,964	-1,931	-1,911	-1,891	-1,868	-1,846	-1,933	-1,916	-1,915	-1,890	-1,860	-1,840	-1,823	-1,781	-1,752	-1,708	-1,652	-1,483	-1,430	-1,391
Additional Paid-In Capital	0.1%	2,088	2,085	2,083	2,080	2,078	1,998	1,996	1,994	1,992	2,023	2,020	2,017	2,014	1,887	1,839	1,802	1,797	1,752	1,745	1,737	1,733
Shares Outstanding	0.5%	250	249	256	255	255	208	201	200	200	198	199	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00
Float	-	-	-	-	177	-	-	-	162	-	-	-	790	-	-	-	435	-	-	-	660	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	10.6%	-14,090	-15,766	-17,008	-15,768	-18,388	-15,396	-23,813	-7,053	-18,783	-14,589	-17,022	-7,776	-16,384	-16,469	-19,004	-13,805	-27,743	-32,142	-27,148	-33,403	-43,234
Share Based Compensation	14.1%	2,581	2,262	2,306	2,189	3,131	2,210	2,125	2,309	3,562	2,442	2,490	3,557	5,415	4,497	4,600	4,897	4,372	4,412	5,423	61.00	9,054
Cashflow From Investing	80.9%	24,045	13,293	10,525	23,503	-50,408	11,421	181,855	16,573	16,568	15,929	22,013	16,620	-129,102	40,184	181	23,967	-36,553	54,509	13,777	-15,027	33,592
Cashflow From Financing	-	-	-	-	-14,585	44,174	-39,282	-115,734	-113	-163	-110	234	23.00	121,040	-72.00	-114	-1,260	34,151	1,199	45.00	-33.00	6,927

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PGEN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Other Income (Expense), Net
Loss before income taxes	$ (23,767)	$ (22,789)
Income tax benefit	29	55
Net loss	$ (23,738)	$ (22,734)
Net loss per share
Net (loss) income per share, basic (in dollars per share)	$ (0.10)	$ (0.10)
Net (loss) income per share, diluted (in dollars per share)	$ (0.10)	$ (0.10)
Weighted average shares outstanding, basic (in shares)	249,220,335	229,770,381
Weighted average shares outstanding, diluted (in shares)	249,220,335	229,770,381
Continuing Operations
Revenues
Total revenues	$ 1,065	$ 1,851
Operating Expenses
Research and development	14,249	12,163
Selling, general and administrative	10,151	11,639
Total operating expenses	25,475	25,329
Operating loss	(24,410)	(23,478)
Other Income (Expense), Net
Interest expense	(2)	(324)
Interest income	608	633
Other income, net	37	380
Total other income, net	643	689
Loss before income taxes	(23,767)	(22,789)
Income tax benefit	29	55
Continuing Operations \| Product revenues
Revenues
Total revenues	138	324
Continuing Operations \| Service revenues
Revenues
Total revenues	919	1,527
Operating Expenses
Cost of products and services	1,075	1,527
Continuing Operations \| Other revenues
Revenues
Total revenues	$ 8	$ 0

PGEN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 17,478	$ 7,578
Short-term investments	27,280	55,277
Receivables
Trade, less allowance for credit losses of $0 and $184 as of March 31, 2024 and December 31, 2023	872	902
Other	290	673
Prepaid expenses and other	3,626	4,325
Total current assets	49,546	68,755
Property, plant and equipment, net	12,620	7,111
Intangible assets, net	38,717	40,701
Goodwill	26,555	26,612
Right-of-use assets	6,658	7,097
Other assets	751	767
Total assets	134,847	151,043
Current liabilities
Accounts payable	4,716	1,726
Accrued compensation and benefits	9,962	8,250
Other accrued liabilities	7,296	6,223
Settlement and indemnification accruals	5,075	5,075
Deferred revenue	407	509
Current portion of lease liabilities	1,318	1,202
Total current liabilities	28,774	22,985
Deferred revenue, net of current portion	1,888	1,818
Lease liabilities, net of current portion	5,387	5,895
Deferred tax liabilities	1,779	1,847
Total liabilities	37,828	32,545
Commitments and contingencies (Note 13)
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 256,398,527 shares issued as of March 31, 2024 and December 31, 2023, $250,248,808 shares and $248,919,096 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.	0	0
Additional paid-in capital	2,088,025	2,084,916
Accumulated deficit	(1,988,209)	(1,964,471)
Accumulated other comprehensive loss	(2,797)	(1,947)
Total shareholders' equity	97,019	118,498
Total liabilities and shareholders' equity	$ 134,847	$ 151,043

About Precigen Inc

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

CEO	Dr. Helen Sabzevari MPH, Ph.D.
WEBSITE	https://precigen.com
INDUSTRY	Biotechnology
EMPLOYEES	209

Precigen Inc Frequently Asked Questions

What is the ticker symbol for Precigen Inc? What does PGEN stand for in stocks?

PGEN is the stock ticker symbol of Precigen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precigen Inc (PGEN)?

As of Fri May 17 2024, market cap of Precigen Inc is 348.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart for subscribers.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart for subscribers. The fair value of Precigen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precigen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precigen Inc a good stock to buy?

The fair value guage provides a quick view whether PGEN is over valued or under valued. Whether Precigen Inc is cheap or expensive depends on the assumptions which impact Precigen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGEN.

What is Precigen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PGEN's PE ratio (Price to Earnings) is -3.59 and Price to Sales (PS) ratio is 15.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Precigen Inc's stock?

In the past 10 years, Precigen Inc has provided -0.22 (multiply by 100 for percentage) rate of return.